Posted by Michael Wonder on 12 Apr 2022
Recursion is granted fast track designation for REC-4881 for the potential treatment of familial adenomatous polyposis
11 April 2022 - Recursion today announced that the U.S. FDA has granted the company fast track designation for REC-4881 for the potential treatment of familial adenomatous polyposis in patients who have previously undergone a colectomy/proctocolectomy.
REC-4881 is an orally bioavailable, non-ATP competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in familial adenomatous polyposis patients.
